Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.
Multiple sclerosis: T-cell resistance to regulation in RRMS linked to IL-6 pathway.
Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis.
Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia.
Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis.
Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis.
Kindlin-3 regulates integrin activation and adhesion reinforcement of effector T cells.
[Will multiple sclerosis (MS) susceptibility genes one day become biomarkers for MS diagnosis?]
Effects of Wii exercises on balance in people with multiple sclerosis.
Vm24, a Natural Immunosuppressant Peptide Potently and Selectively Blocks Kv1.3 Potassium Channels of Human T Cells.
Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.
A Biodegradable Nanoparticle Platform for the Induction of Antigen-Specific Immune Tolerance for Treatment of Autoimmune Disease.
Higher burden of migraine compared to other neurological conditions: results from a cross-sectional study.
Identification of candidate risk gene variations by whole-genome sequence analysis of four rat strains commonly used in inflammation research.
[Vitamin D and multiple sclerosis : The role for risk of disease and treatment.]
Fibronectin aggregation in multiple sclerosis lesions impairs remyelination.
New hope for multiple sclerosis patients.
Chromatin Landscape Defined by Repressive Histone Methylation during Oligodendrocyte Differentiation.
Who receives rehabilitation in canadian long-term care facilities? A cross-sectional study.
Devic's disease before Devic: Bilateral optic neuritis and simultaneous myelitis in a young woman (1874).
A standardized motor imagery introduction program (MIIP) for neuro-rehabilitation: development and evaluation.
Massage therapy and exercise therapy in patients with multiple sclerosis: a randomized controlled pilot study.
Outcome Measures for Individuals With Multiple Sclerosis: Recommendations From the American Physical Therapy Association Neurology Section Task Force.
Notable Increased Cerebrospinal Fluid Levels of Soluble Interleukin-6 Receptors in Neuromyelitis Optica.
Bevacizumab Diminishes Experimental Autoimmune Encephalomyelitis by Inhibiting Spinal Cord Angiogenesis and Reducing Peripheral T-Cell Responses.
Pages
« first
‹ previous
…
303
304
305
306
307
308
309
310
311
…
next ›
last »